Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Aurora Health Care, Aurora Cancer Care
mi
from
West Allis, WI
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Aurora Health Care, Aurora Cancer Care
mi
from
West Allis, WI
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Loyola University Chicago, performing research at Loyola University Medical Center
mi
from
Maywood, IL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Loyola University Chicago, performing research at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Oakland Medical Center
mi
from
Oakland, CA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Oakland Medical Center
mi
from
Oakland, CA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
JDCH Pediatric Oncology and Hematology
mi
from
Hollywood, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
JDCH Pediatric Oncology and Hematology
mi
from
Hollywood, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Cancer Institute Of Florida
mi
from
Orlando, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Cancer Institute Of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Cancer Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Memorial Cancer Institute at Memorial Hospital West
mi
from
Pembroke Pines, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Memorial Cancer Institute at Memorial Hospital West
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins All Children's Hospital IDS Pharmacy
mi
from
Saint Petersburg, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins All Children's Hospital IDS Pharmacy
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins All Children's Outpatient Care Pediatric Hematology/Oncology Department
mi
from
Saint Petersburg, FL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins All Children's Outpatient Care Pediatric Hematology/Oncology Department
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Investigational Drugs Service Pharmacy, Attn. Judy Pi, PharmD, Ami Patel, PharmD
mi
from
Chicago, IL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Investigational Drugs Service Pharmacy, Attn. Judy Pi, PharmD, Ami Patel, PharmD
mi
from
Chicago, IL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
University Of Kansas Cancer Center And Medical Pavillion
mi
from
Westwood, KA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
University Of Kansas Cancer Center And Medical Pavillion
mi
from
Westwood, KA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University (Tju) - Jefferson University Physicians (Jup)
mi
from
Philadelphia, PA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University (Tju) - Jefferson University Physicians (Jup)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University, Investigative Drug Service
mi
from
Philadelphia, PA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University, Investigative Drug Service
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Cancer Center IDS Pharmacy Attn: Lauren Benusa, Pharm D.
mi
from
Charlottesville, VA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Cancer Center IDS Pharmacy Attn: Lauren Benusa, Pharm D.
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven
mi
from
New Haven, CT
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital of Yale New Haven
mi
from
New Haven, CT
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Yale New Haven Hospital Smilow Cancer Center
mi
from
New Haven, CT
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Yale New Haven Hospital Smilow Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
St.Francis Hospital
mi
from
Indianapolis, IN
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
St.Francis Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated:  12/31/1969
Lisa Nakatsu, RPh
mi
from
Seattle, WA
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Status: Enrolling
Updated: 12/31/1969
Lisa Nakatsu, RPh
mi
from
Seattle, WA
Click here to add this to my saved trials
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib
Status: Enrolling
Updated:  12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib
Status: Enrolling
Updated: 12/31/1969
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Clearview Cancer Institute
mi
from
Huntsville, AL
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Southern Cancer Center PC-Mobile
mi
from
Mobile, AL
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Southern Cancer Center PC-Mobile
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Ironwood Cancer TX & Rsch Ctrs
mi
from
Chandler, AZ
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Ironwood Cancer TX & Rsch Ctrs
mi
from
Chandler, AZ
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Center- Aurora
mi
from
Aurora, CO
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Center- Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Cancer Care and Hematology
mi
from
Fort Collins, CO
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Cancer Care and Hematology
mi
from
Fort Collins, CO
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Piedmont Cancer Institute, P.C.
mi
from
Atlanta, GA
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Piedmont Cancer Institute, P.C.
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Central Georgia Cancer Care
mi
from
Macon, GA
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Northwest Georgia Oncology Centers PC - Marietta
mi
from
Marietta, GA
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Northwest Georgia Oncology Centers PC - Marietta
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Cancer Care & Hematology Specialists of Chicagoland
mi
from
Niles, IL
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Missouri-Ellis Fischel; University Hospitals and Clinics
mi
from
Columbia, MO
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Missouri-Ellis Fischel; University Hospitals and Clinics
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Care Associates LLC - Morristown
mi
from
Morristown, NJ
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Care Associates LLC - Morristown
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  12/31/1969
San Juan Oncology Associates
mi
from
Farmington, NM
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 12/31/1969
San Juan Oncology Associates
mi
from
Farmington, NM
Click here to add this to my saved trials